VivoSeq
Other

Necrosis

50

Pipeline Programs↗

8

Active Trials↗

25

Companies Involved↗

Necrosis is a moderately active landscape with 50 programs across 25 companies. The most active players are Pfizer, Sanofi, Daiichi Sankyo. 5 therapies are approved with 12 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

15/100

Mech. Concentration

20/100

Completion Rate

75/100

Attrition Rate

18/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Pfizer logo

Pfizer

2 programs

Phase 2Sanofi logo

Sanofi

1 program

Phase 2Daiichi Sankyo logo

Daiichi Sankyo

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2Shanghai Henlius Biotech logo

Shanghai Henlius Biotech

1 program

Phase 2Novartis logo

Novartis

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical12

Tocilizumab

Roche

Etanercept

Immunex

Anti-TNF Therapy

Takeda

Triamcinolone Acetonide

Bausch Health Americas, Inc.

Hyperbaric Oxygen

Intermountain Health Care, Inc.

Phase 11

Pentoxifylline

Validus Pharmaceuticals

Phase 220

Methylprednisolone

Pfizer

Ds-1205c

Daiichi Sankyo

Cyclophosphamide

Baxter Healthcare Corporation

Bevacizumab

Bio-Thera Solutions

Doxorubicin

Pfizer

Phase 312

Adenosine

Astellas

Dexamethasone

Aspen Global Incorporated

Rosuvastatin

AstraZeneca

Methotrexate

Alnylam Pharmaceuticals

Unfractioned Heparin

Boehringer Ingelheim

Approved5

Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Furosemide

Validus Pharmaceuticals

Botox

AbbVie

Sertraline

Viatris Specialty LLC

Eptifibatide

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Analysis

Modality Breakdown

84%

Small molecule

47 of 56 classified programs — the dominant modality here.

16%ALL OTHERSMonoclonal antibody59%Protein / enzyme24%Peptide12%Vaccine12%

Small molecule leads; the ring shows all 56 classified programs, each share of the total. Modality classified for 100% of 58 pipeline programs.

Analysis

Trial Status

55

clinical trials

Completed30 · 55%
Terminated9 · 16%
Unknown status7 · 13%
Recruiting4 · 7%
Not yet recruiting3 · 5%
Active, not recruiting1 · 2%
Other1 · 2%

Clinical Trials

Trial Activity

55 trials

A Study of Chlorophyllin for the Management of Brain Radio-necrosis in Patients With Diffuse Glioma
Recruiting·TTata Memorial Centre·Phase 2·NCT06016452·118 enrolled
The Efficacy of Bevacizumab and Serplulimab Combined With Recombinant Mutant HumanTumor Necrosis Factor(rmhTNF-NC) in the Treatment of Malignant Ascites
Recruiting·SSun Yat-sen University·Phase 2·NCT06433869·60 enrolled
Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases
Recruiting·IInstitut Cancerologie de l'Ouest·Phase 3·NCT06471465·84 enrolled
Intraperitoneal Injection of Liposomal Irinotecan as Monotherapy or in Combination With Recombinant Mutant Human Tumor Necrosis Factor or Bevacizumab for the Treatment of Malignant Ascites Following Failure of Prior Standard Therapy
Recruiting·—·Phase 1/2·NCT07397819·48 enrolled
Fluorescence-based Detection of Inflammation and Necrosis to Inform Surgical Decision-making and Enhance Outcomes
Active, not recruiting·UUniversity of Wisconsin, Madison·N/A·NCT05593523·100 enrolled
Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF)
Not yet recruiting·—·Phase 2/3·NCT07161843·500 enrolled
Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout
Not yet recruiting·—·N/A·NCT05925166·100 enrolled
Lesion Sterilization and Tissue Repair Antibiotic Paste Versus Zinc Oxide and Eugenol Pulpectomy for Treatment of Primary Molars With Pulp Necrosis
Not yet recruiting·UUniversity of Faisalabad·Phase 1/2·NCT07475364·180 enrolled
18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis
Completed·—·Phase 1·NCT03930173·18 enrolled
Home Treatment of HIV-Infected Patients With Interleukin-2 With or Without a Tumor Necrosis Factor Antagonist
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001475·85 enrolled
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
Completed·UUniversity of Alabama at Birmingham·Phase 2·NCT02538341·617 enrolled
Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers
Completed·UUniversity of Erlangen-Nürnberg Medical School·N/A·NCT02778789·66 enrolled
Rosuvastatin in Preventing Myonecrosis in Elective Percutaneous Coronary Interventions (PCIs)
Completed·UUniversity of Roma La Sapienza·Phase 3·NCT01007279·160 enrolled
Depth of Necrosis in Normal Cervical Epithelium After 85% Trichloroacetic Acid (TCA) Application
Completed·IIndonesia University·N/A·NCT04911075·40 enrolled
ALBION "Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis"
Completed·Sanofi logoSanofi·Phase 2·NCT00360386·110 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)